

Quarterly activities report for January – March 2023

The quarterly activities include details of monitoring and compliance activities by the Office of the Gene Technology Regulator (OGTR) during the quarter.

Monitoring of GMO Dealings involving Intentional Release (DIR)

During the quarter the OGTR did not inspect any GM plant field trial sites.

Monitoring of GMO Dealings Not involving Intentional Release (DNIR), certified facilities and DIR clinical and veterinary trials

During the quarter, the OGTR inspected **four** organisations holding certified facilities (**Table 1**) and **three** organisations holding DNIR licences (**Table 2**).

Table 1 – Summary of organisations and facility types that the OGTR inspected for the January – March 2023 quarter.

Organisation	Physical Containment (PC) level	Number of facilities monitored
The University of Adelaide	PC2 Laboratory	1
South Australian Health and Medical Research Institute	PC2 Laboratory PC2 Animal Facility	2 1
Treidlia Biovet Pty Ltd	PC2 Laboratory	5
Bioproperties Pty Ltd ¹	PC2 Laboratory	1
Total		10

Table 2 – Summary of inspection activities for DNIR licences, DIR clinical and veterinary trial licences for the January – March 2023 quarter.

Licence holder	Licence number
Merck Sharp & Dohme (Australia) Pty Ltd	DNIR 650
South Australian Health and Medical Research Institute	DNIR 627
Treidlia Biovet Pty Ltd	DNIR 640

Practice Reviews, Audits and Investigations

The Monitoring and Compliance section may initiate practice reviews in response to observations made during earlier monitoring activities, or to follow up incident reports or to assess the effectiveness of systems used by licence holders and IBC(s). The objective is to determine if licence conditions can be, and are being, effectively implemented. No practice reviews or investigations were undertaken during the quarter.

¹ Facility was subject to a joint inspection with the Contained Dealings Evaluation Section

During the January – March 2023 quarter the OGTR continued an audit of University of Adelaide in South Australia and the findings will be reported in the Regulator’s Annual Report.

Monitoring and Compliance Findings

Findings from routine monitoring, auditing and investigations, and related enforcement activities, are provided in the Regulator’s Annual Report in accordance with section 136 of the *Gene Technology Act 2000*.